Welcome to our dedicated page for Cumberland Pharmaceuticals SEC filings (Ticker: CPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cumberland Pharmaceuticals Inc. (CPIX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of its financial reporting and material events. As a Nasdaq-listed specialty pharmaceutical company, Cumberland uses these filings to report on its commercial portfolio of FDA-approved brands, clinical programs, and corporate transactions.
Investors can use this page to access annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include discussions of net revenues by product, research and development spending, liquidity, and risk factors relevant to Cumberland’s hospital acute care, gastroenterology, and oncology businesses. These filings also describe the performance of key brands such as Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, Vibativ, and Talicia, along with updates on Phase II ifetroban studies in Duchenne Muscular Dystrophy cardiomyopathy, Systemic Sclerosis, and Pulmonary Fibrosis.
The page also lists current reports on Form 8-K, where Cumberland discloses significant events. Recent 8-Ks reference quarterly financial results, strategic arrangements with RedHill Biopharma to jointly commercialize Talicia, and amendments to a revolving credit facility with Pinnacle Bank that outline borrowing capacity, collateral, and covenant terms.
Users can review proxy statements and other governance-related documents to understand board matters and executive compensation, as well as Form 4 insider transaction reports that detail purchases and sales of CPIX shares by officers, directors, and major shareholders.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify important changes in revenue composition, credit arrangements, clinical program disclosures, and other material information. Real-time updates from EDGAR ensure that new Cumberland filings, including 10-K, 10-Q, 8-K, and Form 4 reports, are added as they become available.
Cumberland Pharmaceuticals (CPIX) director reported a series of open‑market purchases executed automatically under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred on multiple trading days from October 1 to October 31, 2025, with 68 shares acquired each day at prices generally in the $3.14–$3.63 range.
Following these purchases, the reporting person’s directly held stake was 292,595 shares as of October 31, 2025. The filing indicates it was made by a single reporting person serving as a Director, with all holdings shown as Direct (D).
Cumberland Pharmaceuticals (CPIX) reported a strategic arrangement with RedHill Biopharma to jointly commercialize Talicia, an FDA-approved oral capsule for treating Helicobacter pylori infection in adults. The product targets a bacterial infection that is a leading risk factor for gastric cancer.
The company furnished a related press release as Exhibit 99.1 dated October 21, 2025. This update was disclosed under Item 8.01 (Other Events).
Caroline Young, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a sequence of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. Purchases occurred on multiple dates from 09/02/2025 through 09/30/2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported trade on 09/30/2025, the filing shows 33,030 shares beneficially owned by Ms. Young.
The transactions were automatic under the disclosed 10b5-1 plan; the filing is signed by an attorney-in-fact on behalf of Ms. Young and contains no derivative transactions or other compensatory awards. All information is limited to the trades listed and the plan adoption date disclosed in the explanation section.
James Jones, a director of Cumberland Pharmaceuticals Inc (CPIX), reported a series of open-market purchases of common stock executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The transactions occurred daily from September 2, 2025 through September 30, 2025, with reported per-share prices ranging from $3.05 to $3.60. After the final reported purchase on September 30, 2025, the filing shows 44,192 shares beneficially owned by the reporting person. All transactions are reported as acquisitions and are marked as direct ownership.
A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of open-market purchases executed under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported transactions occurred between September 2, 2025 and September 30, 2025, with incremental buys at prices ranging from $3.05 to $3.60. Following the transactions, the filing shows beneficial ownership of 5,700,284 shares. The Form 4 was signed by an attorney-in-fact, John Hamm, on October 3, 2025. The filing identifies the reporting person as a Director, 10% owner, and Chairman and CEO.
Kenneth J. Krogulski, a director of Cumberland Pharmaceuticals Inc. (CPIX), reported a sequence of open-market purchases of the issuer's common stock executed between 09/02/2025 and 09/30/2025. The transactions were completed under a pre-established Rule 10b5-1 trading plan adopted on 11/14/2024 and were executed automatically.
Across multiple dates Mr. Krogulski acquired shares at prices ranging from $3.05 to $3.60, resulting in beneficial ownership of 291,031 shares following the reported transactions. Each purchase is reported as a direct ownership change and the purchases are shown as individual trades on consecutive trading days in September 2025.
Caroline Young, a director of Cumberland Pharmaceuticals Inc. (CPIX), purchased shares of the company in multiple automatic trades executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. The reported purchases occurred across trading dates from July 1 through July 31, 2025, at per-share prices ranging about $3.05 to $3.82. Following the reported transactions, her beneficial ownership increased from 32,661 shares to 32,821 shares, a net gain of 160 shares.
The filing confirms the trades were made pursuant to the pre-established 10b5-1 plan and signed by an attorney-in-fact on behalf of the reporting person. No sales, derivative transactions, or other changes in relationship to the issuer are reported in this Form 4.
James Jones, identified as a director of Cumberland Pharmaceuticals Inc. (CPIX), reported a series of systematic purchases of the issuer's common stock during July 2025. The table discloses multiple acquisitions executed across July 1–31, 2025, with reported transaction prices ranging from $3.05 to $3.82 per share. The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
The Form shows the reporting person’s beneficial ownership rising through the month, culminating at 43,676 shares following the July 31, 2025 purchase. The filing was signed by an attorney-in-fact on behalf of James Jones and discloses the transactions as purchases under the Section 16 reporting requirements.
A.J. Kazimi, Chairman and CEO of Cumberland Pharmaceuticals (CPIX), reported a series of purchases of the company's common stock executed during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. Transactions recorded in the Form 4 run from July 1 through July 31, 2025 at prices shown in the filing ranging from $3.05 to $3.82.
All reported shares are held directly. After the reported transactions, the Form 4 shows beneficial ownership of 5,699,768 shares. The filing identifies the reporting person as a Director, Chairman and CEO and a 10% owner, and notes the purchases occurred automatically pursuant to the 10b5-1 plan.
Kenneth J. Krogulski, a director of Cumberland Pharmaceuticals Inc. (CPIX), executed a series of automated purchases of the company's common stock during July 2025 under a Rule 10b5-1 trading plan adopted on November 14, 2024. Over 22 trading dates from July 1 to July 31, the reporting shows purchases totaling 1,712 shares, increasing his direct beneficial ownership to 288,345 shares. Transaction prices ranged from $3.05 to $3.82, with individual daily purchases of mostly 80 shares and later 68 shares.
The Form 4 indicates these purchases were made automatically pursuant to the previously adopted 10b5-1 plan and that ownership is held directly. No derivative transactions or other classes of securities are reported on this filing.
FAQ
What is the current stock price of Cumberland Pharmaceuticals (CPIX)?
What is the market cap of Cumberland Pharmaceuticals (CPIX)?
